loteprednol etabonate/brimonidine (OCU310) / Ocugen - LARVOL DELTA

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) (clinicaltrials.gov) - P3; N=241; Completed; Sponsor: Ocugen; Recruiting ➔ Completed

Clinical • Trial completion • Dry Eye Disease • Ophthalmology

Dry eye drugs: New approaches to an old problem (Review of Optometry) - "CyclASol is a promising cyclosporine that uses a non-aqueous perfluorobutylpentane technology based on semifluorinated alkanes. This formulation may improve bioavailability of CsA and onset of efficacy. In a Phase II study, CyclASol showed a significant reduction in corneal and conjunctival staining compared with both the vehicle and Restasis with an onset of effect at two weeks."

Online posting

Brimonidine therapy well tolerated for treatment of dry eye disease (Ophthalmology Times) - "The results showed tolerability scores were high and similar across treatment groups and study visits, said Dr. Majmudar...There was no statistically significant difference in tolerability between each treatment group and the placebo group at the day 84 visit, which met the pre-specified primary endpoint."

Media quote

Newly added product (Ocugen Press Release) - P3, Dry Eye Disease

Pipeline update